Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4143653 | 0.99 | KCNH2 (0.60) | KCNH2PIK3CAMTORADORA2ACYP1A2 | |
| SCHEMBL10313861 | 0.91 | KCNH2 (0.52) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4135969 | 0.90 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL18117306 | 0.86 | KCNH2 (0.58) | KCNH2PIK3CAMTORADORA2ACYP1A2 | |
| SCHEMBL18544187 | 0.85 | KCNH2 (0.56) | KCNH2ADORA2ACYP1A2TSHR | |
| SCHEMBL18544186 | 0.85 | KCNH2 (0.56) | KCNH2ADORA2ACYP1A2TSHR | |
| SCHEMBL12090938 | 0.85 | KCNH2 (0.46) | KCNH2PIK3CAMTORADORA2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL18529086 | 0.85 | KCNH2 (0.55) | KCNH2ADORA2ACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL18529085 | 0.85 | KCNH2 (0.55) | KCNH2ADORA2ACYP1A2TSHR | |
| SCHEMBL18544260 | 0.84 | KCNH2 (0.56) | KCNH2CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| EP-2044077-B1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2015-10-08 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885PIK3CA 851/4885MTOR 2238/4885 |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | KCNH2 4625/4885PIK3CA 2837/4885MTOR 2199/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885PIK3CA 2470/4885MTOR 1971/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | KCNH2 248/4885PIK3CA 3365/4885MTOR 4016/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | KCNH2 260/4885PIK3CA 3669/4885MTOR 4110/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885PIK3CA 851/4885MTOR 2238/4885 |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | KCNH2 4625/4885PIK3CA 2837/4885MTOR 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.